読み込み中
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
前日終値
$22.59
+$0.05 · +0.22%
日中の時刻はETです。市場データは遅延する場合があります。
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
日中レンジ
現在 $22.59
52週レンジ
現在 $22.59
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
2
著しい割高
センチメント
62
強気
リスク
58
やや高いリスク
モメンタム
65
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
日中レンジ
現在 $22.59
52週レンジ
現在 $22.59
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1609.8万 USD | 2711.9万 USD | 1584.3万 USD | 1.06億 USD | 5.24億 USD |
| 売上原価 | 168.6万 USD | 1832.7万 USD | 1362.8万 USD | 334.3万 USD | 2497.6万 USD |
| 粗利益 | 1441.2万 USD | 879.2万 USD | 221.5万 USD | 1.03億 USD | 4.99億 USD |
| 研究開発 | 1.41億 USD | 1.44億 USD | 2.15億 USD | 1.98億 USD | 1.44億 USD |
| 販売・一般管理 | 6533.7万 USD | 5068.2万 USD | 7307.9万 USD | 5469.8万 USD | 5629万 USD |
| 営業費用 | 2.02億 USD | 1.93億 USD | 2.85億 USD | 2.46億 USD | 1.88億 USD |
| 受取利息 | 1696.7万 USD | 2141.5万 USD | 1956.2万 USD | 60.9万 USD | 16.2万 USD |
| 支払利息 | 6199.4万 USD | 6374.1万 USD | 4155.7万 USD | 1170.4万 USD | 747.4万 USD |
| 減価償却費と償却費 | 1475.9万 USD | 1264.1万 USD | 1190万 USD | 853.7万 USD | 729.9万 USD |
| 営業利益 | −1.88億 USD | −1.84億 USD | −2.83億 USD | −1.43億 USD | 3.11億 USD |
| 純利益 | −1.99億 USD | −2.4億 USD | −3.08億 USD | −1.27億 USD | 3.3億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$52.60
上昇余地（132.85%）この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P Biotech ETFXBI4640.93万0.47%98.74億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF3847.48万0.04%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB1126.02万0.11%108.2億 USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA827.39万0.04%218.24億 USD0.03%$32.79+0.40%
Vanguard Health Care ETFVHT766.19万0.03%220億 USD0.09%$319.01+1.64%
Invesco Dorsey Wright Healthcare Momentum ETFPTH298.62万1.04%2.87億 USD0.74%$58.757+2.42%
Direxion Daily S&P Biotech Bull 3X SharesLABU218.55万0.37%5.97億 USD0.96%$243.09+9.01%
iShares Core S&P Total U.S. Stock Market ETFITOT201.38万0.00%980.88億 USD0.03%$169.66+0.64%State Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTInvesco Dorsey Wright Healthcare Momentum ETFPTHDirexion Daily S&P Biotech Bull 3X SharesLABUiShares Core S&P Total U.S. Stock Market ETFITOTAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
